Business Context and Reporting Period
Company: Impact Biomedical Inc. (IBO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Impact Biomedical discovers, patents, and licenses biopharmaceutical and wellness technologies. Key platforms include Linebacker (oncology/neurology), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral). The company operates as a single segment and relies on licensing, co-development, and direct sales for revenue generation.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $32,000 | $0 |
| Net Loss | $(11,870,000) | $(24,770,000) |
| Operating Loss | $(4,282,000) | $(28,753,000) |
| Cash and Cash Equivalents (End of Period) | $3,000 | $1,999,000 |
| Total Assets | $17,405,000 | $20,290,000 |
| Total Liabilities | $1,850,000 | $13,053,000 |
| Stockholders' Equity | $15,555,000 | $7,237,000 |
Note: Revenue consists of $32,000 in biotech retail sales from the Celios air purification technology acquired in Q1 2025.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 52% to $11.87 million, primarily due to the absence of the $25.1 million goodwill impairment recorded in 2024. However, this was partially offset by a $9.4 million loss on the change in fair value of a related-party note payable.
- Debt Conversion: In October 2025, the company converted approximately $15 million of outstanding principal and interest debt owed to DSS, Inc. into 31,939,778 shares of common stock. This eliminated the related-party note payable liability but resulted in a significant fair value adjustment loss.
- Expense Fluctuations:
- Professional Fees: Increased 125% to $1.0 million due to merger/acquisition due diligence and business plan execution.
- Sales & Marketing: Decreased 96% to $24,000 as the company reduced travel and entertainment costs.
- Cost of Revenue: New line item of $424,000 related to the Celios acquisition; includes a $419,000 inventory impairment.
- Liquidity: Cash reserves dropped significantly from ~$2.0 million to $3,000, driven by operating cash outflows of $1.9 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing includes a "Substantial Doubt" regarding the company's ability to continue as a going concern within one year due to operating losses and negative cash flows. Management plans to monetize IP and control costs to address this.
- Strategic Merger: The company announced a definitive merger agreement to be acquired by Dr. Ashleys Limited in a reverse merger, aiming to combine manufacturing capabilities with IBO's patent portfolio.
- Acquisition: Acquired Celios Air Purification technology assets in Q1 2025 for $1.15 million (paid in stock), introducing a new revenue stream but also inventory impairment risks.
- Internal Controls: Management concluded that disclosure controls and internal controls over financial reporting were not effective as of December 31, 2025, citing insufficient accounting personnel and lack of segregation of duties.
- Intellectual Property: The company holds 69 issued patents and over 60 pending patents. Revenue remains contingent on successful licensing and commercialization by partners (e.g., ProPhase Laboratories, Chemia).
Investor Verification Checklist
- Cash Runway: Verify the immediate liquidity position given cash balances of only $3,000 and the "going concern" warning.
- Merger Status: Confirm the progress and regulatory approval status of the proposed reverse merger with Dr. Ashleys Limited.
- Debt Settlement: Review the terms of the debt-to-equity conversion with DSS, Inc. to ensure no hidden liabilities remain.
- Revenue Sustainability: Assess the viability of the Celios air purification sales ($32k revenue vs. $424k cost) and the timeline for milestone payments from licensing partners.
- Internal Controls: Monitor the remediation plan for material weaknesses in financial reporting and segregation of duties.